title: Taurocholic acid feeding prevents tumor necrosis factor-alpha-induced damage of cholangiocytes by a PI3K-mediated pathway.
abstract: Cholangiopathies, such as primary biliary cirrhosis and primary sclerosis cholangitis, are characterized at the end stage by ductopenia due to increased cholangiocyte apoptosis and decreased cholangiocyte proliferation. Although cholangiocyte proliferation is associated with an increased number of intra-hepatic bile ducts and secretin-stimulated ductal secretion, ductopenia is coupled with decreased ductal mass and secretin-induced ductal secretory activity. We have shown that a single injection of actinomycin D + tumor necrosis factor-alpha (TNF-alpha ) to bile duct-ligated (BDL) rats induces cholangiocyte injury, which is characterized by loss of cholangiocyte proliferation, and secretory activity and by an increase in cholangiocyte apoptosis. We also have shown that taurocholic acid both in vivo and in vitro stimulates cholangiocyte proliferation. We hypothesize that taurocholic acid feeding protects cholangiocytes against TNF-alpha -induced apoptosis through a phosphatidylinositol-3-kinase (PI3K)-dependent pathway. Immediately after BDL, rats were fed taurocholic acid or control diet in the absence/presence of daily injections of wortmannin for 1 week. Seven days later, control-fed or taurocholic acid-fed rats were treated with a single intraperitoneal injection of actinomycin D + TNF-alpha . Twenty-four hours later we evaluated: (i) cholangiocyte apoptosis and proliferation in liver sections and (ii) basal and secretin-stimulated bile and bicarbonate secretion in bile fistula rats. Taurocholic acid feeding prevented TNF-alpha -induced increases in cholangiocyte apoptosis and decreases in growth and secretin-stimulated bile and bicarbonate secretion, changes that were blocked by PI3K inhibition. The PI3K survival pathway is important in bile acid protection against immune-mediated cholangiocyte injury in cholestatic liver diseases.
authors.affiliation: Department of Medicine, Tohoku University School of Medicine, Aobaku, Sendai, Japan.
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Ueno
authors.forename: Heather
authors.initials: H
authors.lastname: Francis
authors.forename: Shannon
authors.initials: S
authors.lastname: Glaser
authors.forename: Sharon
authors.initials: S
authors.lastname: Demorrow
authors.forename: Julie
authors.initials: J
authors.lastname: Venter
authors.forename: Antonio
authors.initials: A
authors.lastname: Benedetti
authors.forename: Giammarco
authors.initials: G
authors.lastname: Fava
authors.forename: Marco
authors.initials: M
authors.lastname: Marzioni
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Alpini
mesh_terms: D000818:Animals; D017209:Apoptosis; D001647:Bile Acids and Salts / Q000378:metabolism*; D001652:Bile Ducts / Q000166:cytology* / Q000378:metabolism*; D049109:Cell Proliferation; D007328:Insulin / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D051381:Rats; D011916:Rats, Inbred F344; D012633:Secretin / Q000378:metabolism; D013656:Taurocholic Acid / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D001647:Bile Acids and Salts; D007328:Insulin; D014409:Tumor Necrosis Factor-alpha; D012633:Secretin; D013656:Taurocholic Acid; D019869:Phosphatidylinositol 3-Kinases